JANX EBITDA | Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (JANX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$31.69M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$34.21M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$35.25M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$45.12M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$31.69M	(m)	(m)	(m)	$202.00K*	$12.48M*	(m)	$30.99M	(m)	(m)
2026-03-31	Reported	(m)	-$34.21M	(m)	(m)	(m)	$273.00K	-$12.34M	(m)	$26.81M	(m)	(m)
2025-09-30	Reported	(m)	-$35.25M	(m)	(m)	(m)	$93.00K*	-$12.86M*	(m)	$34.63M	(m)	(m)
2025-06-30	Reported	(m)	-$45.12M	(m)	(m)	(m)	$473.00K*	-$23.81M*	(m)	$34.66M	(m)	(m)
2025-03-31	Reported	(m)	-$34.90M	(m)	(m)	(m)	$371.00K	-$17.02M	(m)	$25.05M	(m)	(m)
2024-09-30	Reported	(m)	-$35.84M	(m)	(m)	(m)	$25.00K*	-$2.23M*	(m)	$18.61M	(m)	(m)
2024-06-30	Reported	(m)	-$13.82M	(m)	(m)	(m)	$95.00K*	-$10.02M*	(m)	$14.90M	(m)	(m)
2024-03-31	Reported	(m)	-$20.16M	(m)	(m)	(m)	$197.00K	-$14.84M	(m)	$14.07M	(m)	(m)
2023-09-30	Reported	(m)	-$15.81M	(m)	(m)	(m)	$470.00K*	-$11.71M*	(m)	$11.89M	(m)	(m)
2023-06-30	Reported	(m)	-$20.75M	(m)	(m)	(m)	$580.00K*	-$15.05M*	(m)	$14.92M	(m)	(m)
2023-03-31	Reported	(m)	-$20.28M	(m)	(m)	(m)	$285.00K	-$13.91M	(m)	$15.87M	(m)	(m)
2022-09-30	Reported	(m)	-$18.02M	(m)	(m)	(m)	$2.52M*	-$13.41M*	(m)	$13.74M	(m)	(m)
2022-06-30	Reported	(m)	-$17.26M	(m)	(m)	(m)	$898.00K*	-$6.07M*	(m)	$14.09M	(m)	(m)
2022-03-31	Reported	(m)	-$13.54M	(m)	(m)	(m)	$971.00K	-$11.52M	(m)	$10.18M	(m)	(m)
2021-09-30	Reported	(m)	-$10.90M	(m)	(m)	(m)	$77.00K*	-$5.85M*	(m)	$8.41M	(m)	(m)
2021-06-30	Reported	(m)	-$6.25M	(m)	(m)	(m)	$79.00K*	-$6.20M*	(m)	$4.74M	(m)	(m)
2021-03-31	Reported	(m)	-$2.28M	(m)	(m)	(m)	$153.00K	$5.56M	(m)	$1.93M	(m)	(m)
2020-09-30	Reported	(m)	-$1.26M	(m)	(m)	(m)	$0.00*	-$1.08M*	(m)	$834.00K	(m)	(m)
2020-06-30	Reported	(m)	-$1.11M	(m)	(m)	(m)	(m)	(m)	(m)	$673.00K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$157.67M	(m)	(m)	(m)	$1.04M	-$82.23M	(m)	$125.90M	(m)	$0.00
2024-12-31	Reported	(m)	-$98.85M	(m)	(m)	(m)	$359.00K	-$43.81M	(m)	$68.39M	(m)	$0.00
2023-12-31	Reported	(m)	-$72.98M	(m)	(m)	(m)	$1.85M	-$50.58M	(m)	$54.92M	(m)	$0.00
2022-12-31	Reported	(m)	-$67.09M	(m)	(m)	(m)	$6.45M	-$42.92M	(m)	$53.44M	(m)	(m)
2021-12-31	Reported	(m)	-$32.93M	(m)	(m)	(m)	$1.48M	-$16.98M	(m)	$26.24M	(m)	(m)
2020-12-31	Reported	(m)	-$4.84M	(m)	(m)	(m)	$0.00	-$4.37M	(m)	$3.04M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Pacira BioSciences, Inc. (PCRX)	United States	$1.020B	69.03
MoonLake Immunotherapeutics (MLTX)	Switzerland	$1.031B	-5.43
Savara Inc (SVRA)	United States	$1.044B	-9.10
Corvus Pharmaceuticals, Inc. (CRVS)	United States	$0.994B	-23.25
MANNKIND CORP (MNKD)	United States	$1.058B	-30.41
Alto Neuroscience, Inc. (ANRO)	United States	$1.065B	-11.02
Kura Oncology, Inc. (KURA)	United States	$0.967B	-3.29
Arbutus Biopharma Corp (ABUS)		$0.965B	6.19
Jade Biosciences, Inc. (JBIO)	United States	$0.936B	-9.21
Amphastar Pharmaceuticals, Inc. (AMPH)	United States	$1.116B	10.93